Trastuzumab/Hyaluronidase-oysk: A New Option for Patients With HER2-Positive Breast Cancer.

Marissa R DucoJoshua L MurdockDavid J Reeves

Published in: The Annals of pharmacotherapy (2019)

SQ trastuzumab has a similar safety profile to IV trastuzumab. Although it may be slightly more cost-effective, its role in the treatment of HER2-overexpressing tumors requires further study in those at the extremes of body weight due to differences in drug exposure compared to IV trastuzumab.

Keyphrases

epidermal growth factor receptor
body weight
metastatic breast cancer
positive breast cancer
adverse drug
smoking cessation
replacement therapy
electronic health record